Millennium reports 2.7% stake in Phathom Pharma
Phathom Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that several Millennium-affiliated entities report passive, sub-5% positions in its common stock as of 12/31/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Phathom Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that several Millennium-affiliated entities report passive, sub-5% positions in its common stock as of 12/31/2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 1,255,161 shares, representing 1.6% of the class, with shared voting and dispositive power over those shares. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 2,082,180 shares, or 2.7% of the class, all with shared voting and dispositive power. The filers state that the securities are not held for the purpose of changing or influencing control of Phathom Pharmaceuticals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Phathom Pharmaceuticals (PHAT) does Millennium report?
Is the Millennium stake in Phathom Pharmaceuticals reported as passive?
Who are the reporting persons on this Phathom Pharmaceuticals Schedule 13G/A?
What type of securities do the reporting persons hold in Phathom Pharmaceuticals (PHAT)?
What does Item 5 indicate about Millennium’s ownership level in Phathom Pharmaceuticals?
AI-generated analysis. How Rhea-AI works. Not financial advice.